View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 4, 2022

Novotech is CRO for Skye’s Phase I glaucoma drug trial

Skye plans to start the first-in-human Phase I trial of SBI-100 in the second quarter of this year.

Skye Bioscience has signed an agreement under which Novotech Health will serve as contract research organisation (CRO) for the upcoming Phase I clinical trial of the former’s drug candidate SBI-100 to treat glaucoma in Australia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Skye plans to commence the first-in-human Phase I trial in the second quarter with results anticipated in the second half of this year. Furthermore, it intends to begin a Phase II proof-of-concept trial before the end of this year.

Under the deal, Novotech will aid investigators in areas of the trial including feasibility analyses, statistical assessment, ethics committee and regulatory filings, medical monitoring.

Additionally, the company will support other aspects of the study including safety services, managing data, central lab services, reporting as well as managing the project and vendors. A full-service biotech specialist CRO, Novotech has experience in the Asia-Pacific region. 

Skye Bioscience CEO Punit Dhillon said: “We are pleased to bring on one of Asia-Pacific’s premier biotech specialist CROs to support our first-inhuman clinical study. 

“With Novotech’s extensive experience in conducting clinical trials, we are optimally positioned to execute this Phase I programme of SBI-100 in Australia where we expect to conduct this important phase of our development quickly and cost-effectively.”

Skye is currently working on a product and clinical development strategy to realise the complete potential of cannabinoids to treat glaucoma and ailments with substantial unmet needs. 

A prodrug of tetrahydrocannabinol (THC), SBI-100 is a topical formulation being developed for the treatment of glaucoma. 

By applying rational drug design, Skye chemically altered THC to develop a synthetic molecule to safely realise THC’s recognised positive effects. 

SBI-100 facilitates improved local administration of the drug into the eye, less systemic side effects and the possibility for neuroprotection. 

The drug candidate was found to offer an improved reduction in intraocular pressure versus various currently marketed classes of drugs, in preclinical studies.

Intraocular pressure is a crucial cause of vision loss and the preclinical data indicates SBI-100’s ability as a transformative therapy option for glaucoma globally.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena